2
项与 HIV vaccine(PX Therapeutics SA) 相关的临床试验Phase 1 Randomised, Single-centre, Observer-blind, Placebo-controlled Trial of Safety and Immunogenicity of EN41-UGR7C HIV Vaccine Candidate Administered Intramuscularly in Healthy Female Volunteers
The purpose of the clinical trial is to evaluate the safety and immunogenicity in female volunteers of EN41-UGR7C vaccine candidate adjuvanted with Alum using IM administration. The objective of the immunisation is to induce mucosal and systemic binding and neutralizing antibodies against HIV in order to block the virus on the mucosal surface and neutralise the viral particles that may eventually succeed in crossing the mucosal barrier.
This is a Phase 1 exploratory study. EN41-UGR7C will be administered for the first time in humans.
Volunteers who are vaccinated with EN41-UGR7C may develop an immune response against HIV, but its ability to induce meaningful protection against HIV will not be known before Phase 3 efficacy trials are completed, as correlates of protection against HIV are not yet clearly defined.
Consequently, there is no direct benefit to volunteers. They will be reimbursed for their time and travel.
Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers
Objectives:
To assess the safety of three priming immunisations by nasal route followed by two booster immunisations by intramuscular route
To assess immunogenicity responses induced by the vaccine.
100 项与 HIV vaccine(PX Therapeutics SA) 相关的临床结果
100 项与 HIV vaccine(PX Therapeutics SA) 相关的转化医学
100 项与 HIV vaccine(PX Therapeutics SA) 相关的专利(医药)
1
项与 HIV vaccine(PX Therapeutics SA) 相关的文献(医药)Adsorptive separation of para-xylene by nonporous adaptive crystals of phenanthrene[2]arene
Article
作者: Ding, Man-Hua ; Tang, Lin-Li ; Duan, Yin-Rong ; Zeng, Fei ; Hou, Ying
A new method for the preparation of phenanthrene[2]arene on a large-scale was developed. The synthetic phenanthrene[2]arene has been successfully used as nonporous adaptive crystals for the separation of para-xylene from xylene isomers.
100 项与 HIV vaccine(PX Therapeutics SA) 相关的药物交易